Establishment Labs Holdings Inc. (ESTA) is a global medical technology company with a primary focus on improving patient safety and aesthetic outcomes. The company has significantly distinguished itself as a trailblazer in the field, specifically in the manufacturing of silicone-filled breast and body shaping implants.
Founded in 2004, the company is headquartered in San Jose, Costa Rica, but also operates from Costa Rica, Florida, Belgium, and the Netherlands. The activities of ESTA are internationally widespread, with more than 70 countries worldwide benefitting from the company's high-quality, innovative products.
ESTA is recognized for the invention and commercialization of Motiva Implants®, the flagship product of the company. These implants are renowned for their advanced, state-of-the-art Ergonomix® design. The Ergonomix® design excellently mimics the look, feel, and movement of natural breasts, and the implants are composed of a proprietary silicone gel which further enhances the natural aesthetic.
In its commitment to prioritizing patient safety, Establisment Labs developed the MotivaImagine® Platform, a unique combination of technologies and services that seek to reduce the common complications associated with implants surgeries. It integrates Q Inside Safety Technology™, a radiofrequency identification (RFID) microtransponder that gives surgeons and patients access to implant-specific data before and after surgery.
Another pivotal achievement is their Q portfolio, which includes products such as the Q Inside Safety Technology (QIST), MotivaEdge, and Q Traceability. The QIST technology enables implant security and traceability, providing vital information about the implant such as manufacturing data and life cycle when scanned with a Q reader.
In a bid to further contribute to science and increase patient safety, the company established the MotivaEdge program, a platform that provides certified education and training for healthcare professionals globally.
ESTA continues to uphold high scientific standards through its activities. In 2018, the Establishment Labs initiated the Motiva Implants® Post Approval Study in the United States, a part of its commitment to clinical science and quantitative evidence to support the safety and efficiency of its products.
Notably, ESTA works in compliance with international regulatory standards, maintaining various registrations, approvals, and certifications such as ISO 13485 and FDA registration. It continues to thrive and forge ahead, reflecting its commitment to innovation, quality, and patient safety in the field of medical technology.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Establishment Labs (ESTA) is presented as a compelling investment for growth investors, transitioning from a cash-burning phase to potentially sustainable profitability. The article highlights its strong revenue growth, expanding gross margins, and strategic global product rollout, despite current operating losses and institutional caution due to persistent GAAP net losses and high short interest. The company's recent scientific advancements and raised full-year revenue guidance suggest a positive trajectory, but investors are awaiting solidified metrics to confirm its long-term viability.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) is showing strong near-term sentiment with a potential for neutrality mid-term and a positive long-term bias. The stock is currently testing support, with an exceptional 62.4:1 risk-reward setup targeting an 18.4% gain versus 0.3% risk. AI models have generated distinct trading strategies, including position trading, momentum breakout, and risk hedging, alongside a multi-timeframe signal analysis.
Establishment Labs Holdings Inc. has appointed Taylor Harris to its Board of Directors, recognizing his 25 years of experience in corporate finance, executive leadership, and board governance across the healthcare, medical technology, and life sciences sectors. Harris, who previously served as CEO of Cutera Inc. and CFO at MyoKardia and Zeltiq Aesthetics, is expected to guide Establishment Labs through its next phase of growth in the global aesthetics market. Establishment Labs is a global medical device company focused on improving women's health through innovative solutions in breast aesthetics and reconstruction.
Establishment Labs Holdings (ESTA) reported strong Q2 2026 results with increased sales to US$67.54 million and a narrowed net loss of US$11.75 million, leading to raised full-year 2026 revenue guidance to US$269-US$271 million. This positive update suggests growing operational momentum for its Motiva implants. While the improved outlook strengthens the bull case, investors are still cautioned about ongoing cash burn and potential future capital raises, despite analyst optimism for revenue and earnings by 2029.
Citigroup has upgraded its rating for Establishment Labs Holdings Inc. to 'Buy' from 'Neutral', setting a new price target of $92. This upgrade follows the company's recent Q2 2026 earnings report, where it exceeded revenue estimates and raised its full-year 2026 earnings guidance. Establishment Labs, a medical technology company focused on women's health, also saw its stock added to several Russell indices.
Baron Discovery Fund strategically trimmed its investment in Establishment Labs Holdings Inc. (ESTA) during Q2 2026 after shares neared its long-term valuation targets, locking in gains from significant share price movement. ESTA, a medical device company focused on breast implants, saw strong adoption of its Motiva implants and benefited from inclusion in the Russell 2000 Index. Despite ESTA's potential, the fund believes certain AI stocks offer greater upside and less downside risk.
Assenagon Asset Management S.A. significantly increased its stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 164.9% in the second quarter, now owning 135,897 shares valued at $11.66 million. Other institutional investors also adjusted their positions in the company. Establishment Labs' stock opened at $75.06, with analysts predicting a moderate buy rating and an average price target of $100.25.